People moves: Biopharma finance & accounting
CatalYm, a clinical stage biopharma in cancer and cachexia, announced Clinton Musil as its chief financial officer and chief business officer. The appointment comes at a time when the company is preparing to advance its solid tumor therapy into late-stage development.
Musil joins from Skyhawk Therapeutics, where he held several roles of increasing responsibility. Musil has completed multiple IPOs as an executive and held several roles at public biotech companies including at ARMO Biosciences, which was acquired by Eli Lilly for $1.6 billion. He holds an MBA from Harvard Business School and BSc in Molecular and Cellular Biology from the University of Arizona.
Enanta Pharmaceuticals announced the passing of its longtime chief financial and administrative officer Paul J. Mellett Jr. Jay R. Luly, PhD, president and CEO of the company said in a statement, “Since joining the Company more than two decades ago, Paul’s leadership and generosity of spirit have been at the core of Enanta.” He credited Mellett with establishing the company’s finance department and bringing critical expertise that shaped Enanta’s growth and success, including its IPO in 2013. Earlier in his career, Mellett was employed with Deloitte & Touche LLP serving as audit partner. He graduated from Boston College.
Harry R. Trout, III, and Kathleen S. Capps, CPA, have been appointed as the Enanta’s principal financial officer and principal accounting officer, respectively, in each case on an interim basis. Enanta is a clinical stage biotech creating oral drugs in the virology and immunology space.
IQVIA, provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, announced that Michael Fedock, currently senior vice president of financial planning & analysis, has been appointed executive vice president and chief financial officer, effective February 28, 2026. He will succeed Ron Bruehlman, who will retire as CFO, who has been with the company since 2011. Bruehlman will continue to serve as senior advisor to CEO Ari Bousbib.
Fedock joined IQVIA in 2016 and has held several senior financial roles, including CFO of IQVIA’s Research & Development Solutions business unit and CFO of IQVIA Laboratories. Prior to joining IQVIA, Fedock served in various leadership roles at ICON plc and other healthcare organizations. Fedock holds a Master of Business Administration from the University of Baltimore and a BSc in Biological Sciences from Drexel University.
Perspective Therapeutics, a clinical-stage radiopharmaceutical company for cancer treatments, has named Joel Sendek as chief financial officer. Sendek previously served as CFO at Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. In addition to raising over $2.5B in these biotechs as CFO, he has also held equity research roles at Stifel Lazard and Oppenheimer. He has a BA in biochemistry from Rice University. Sendek succeeds Juan Graham in his role.
Clinical-stage biopharmaceutical company Resolution Therapeutics, which focuses on novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, has appointed Lucy Singah as chief financial officer. Singah has over 20 years of corporate and strategic finance experience, across both UK and US start-ups and global companies. She most recently served as CFO of Echopoint Medical, and has deep expertise in financial planning, investor relations and overseeing multiple successful fundraising rounds. She also was with GSK for 11 years, where she held roles in M&A, investor relations, and finance leadership in procurement and consumer healthcare. She graduated from the University of Nottingham in management studies.
These announcements are from September 1 through September 22, 2025, as posted on BusinessWire, PRNewswire or Yahoo Finance. If your company has an executive appointment announcement related to finance and accounting, please forward to Brandy Fidler at [email protected]
link
